Table 3.

Circulating metabolites and insulin before and after AXOS and Placebo intervention.

Variables		AXOS (n = 24)	Placebo (n = 24)		P
Fasting
Glucose, mmol/L	Pre	4.93 ± 0.06		4.95 ± 0.05	.586
	Post	4.94 ± 0.05		4.98 ± 0.05
TAG, μmol/L	Pre	813 ± 56		896 ± 103	.534
	Post	706 ± 59		860 ± 119
FFA, μmol/L	Pre	547 ± 37		536 ± 41	.961
	Post	567 ± 50		553 ± 38
Glycerol, μmol/L	Pre	81.5 ± 8		84.4 ± 7	.410
	Post	91.0 ± 11		83.7 ± 7
Insulin, mU/L	Pre	8.4 ± 0.6		8.8 ± 0.9	.821
	Post	7.8 ± 0.6		7.9 ± 0.5
Postprandial (0–5 h) plasma metabolites
Glucose, iAUC/min	Pre	0.11 ± 0.09		0.32 ± 0.01	.576
	Post	0.14 ± 0.09		0.27 ± 0.09
TAG, iAUC/min	Pre	117 ± 24		179 ± 22	.183
	Post	175 ± 39		177 ± 21
FFA, iAUC/min	Pre	−268 ± 31		−243 ± 33	.620
	Post	−302 ± 42		− 253 ± 24
Glycerol, iAUC/min	Pre	−15 ± 5		−22 ± 6	.171
	Post	−25 ± 9		−17 ± 5
Insulin, iAUC 0-5 h/min	Pre	23.1 ± 2.5		20.4 ± 1.9	.316
	Post	22.5 ± 2.6		22.1 ± 2.1

Data are mean ± SEM and analyzed using 2-way repeated measure ANOVA with time (pre/post) and intervention as covariates. P-value represent time*intervention interaction. There were no differences between groups as a result of intervention. TAG Triacylglycerol, FFA free fatty acids, iAUC incremental area under the curve, AXOS Arabinoxylan-Oligosaccharides